Company: EDSA
Filing Date: 2025-09-09
Form Type: 424B5
Source: 0001171843-25-005799
Chunk: 14

Company: Edesa Biotech, Inc.
Filing Date: 2025-09-09
Form: 424B5
Chunk 14
---
 the final determination by our board of directors, there is no minimum or maximum sales price
for shares to be sold in this offering. Investors may experience a decline in the value of the shares they purchase in this offering as
a result of sales made at prices lower than the prices they paid.

**The actual number of shares we will issue
under the Sales Agreement at any one time or in total, is uncertain.**

Subject to certain limitations in the
Sales Agreement and compliance with applicable law, we have the discretion to deliver placement notices to the Sales Agent at any time
throughout the term of the Sales Agreement. The number of shares that are sold by Wainwright as our Sales Agent after we deliver a placement
notice will fluctuate based on the market price of the common shares and the trading volume of our common shares during the sales period
and limits we set with the Sales Agent.

**You may experience future dilution as a result
of future equity offerings.**

In order to raise additional capital,
we may in the future offer additional common shares or other securities convertible into or exchangeable for our common shares at prices
that may not be the same as the price per share in this offering. We may sell shares or other securities in another offering at a price
per share that is less than the price per share paid by the investors in this offering, and investors purchasing shares or other securities
in the future could have rights superior to existing shareholders. The price per share at which we sell additional common shares, or securities
convertible or exchangeable into common shares, in future transactions may be higher or lower than the price per share paid by investors
in this offering. If any of the above should occur, our shareholders, including investors who purchase common shares in this offering,
will experience additional dilution, and any such issuances may result in downward pressure on the price of our common shares.

**We do not currently intend to pay dividends
on our common shares in the foreseeable future, and consequently, any gains from an investment in our common shares will likely depend
on appreciation in the price of our common shares.**

We have never declared or paid cash
dividends on our common shares and do not anticipate paying any cash dividends to holders of our common shares in the foreseeable future.
Consequently, investors must rely on sales of their common shares after price appreciation, which may never occur, as the only way to
realize any future gains on their investments. There is no guarantee that our common shares will appreciate in